Soumit Roy
Stock Analyst at Jones Trading
(1.50)
# 3,361
Out of 4,893 analysts
42
Total ratings
18.75%
Success rate
-6.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
TARA Protara Therapeutics | Initiates: Buy | $21 | $3.12 | +573.08% | 1 | May 22, 2025 | |
AVBP ArriVent BioPharma | Initiates: Buy | $40 | $22.00 | +81.82% | 1 | May 20, 2025 | |
ELVN Enliven Therapeutics | Maintains: Buy | $36 → $27 | $22.75 | +18.68% | 2 | May 16, 2025 | |
ACRV Acrivon Therapeutics | Downgrades: Hold | n/a | $1.35 | - | 2 | May 16, 2025 | |
ONCY Oncolytics Biotech | Downgrades: Hold | n/a | $1.12 | - | 2 | May 16, 2025 | |
MURA Mural Oncology | Downgrades: Hold | n/a | $2.48 | - | 2 | Mar 25, 2025 | |
CRVO CervoMed | Upgrades: Buy | $15 | $7.21 | +108.04% | 3 | Mar 13, 2025 | |
NUVB Nuvation Bio | Initiates: Buy | $10 | $2.31 | +332.90% | 1 | Mar 12, 2025 | |
BEAM Beam Therapeutics | Upgrades: Buy | $34 | $22.03 | +54.34% | 2 | Mar 10, 2025 | |
INAB IN8bio | Upgrades: Buy | $36 | $2.29 | +1,472.05% | 4 | Feb 11, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $2.55 | +1,154.90% | 1 | Jan 28, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.73 | - | 1 | Nov 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $8.37 | +7.59% | 1 | Oct 31, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $11.45 | +48.47% | 1 | Oct 31, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $3.06 | +324.84% | 1 | Sep 17, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $4 | $0.74 | +440.69% | 2 | Sep 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.16 | - | 2 | Jul 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $6.31 | - | 1 | May 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $7.84 | +231.84% | 2 | Apr 17, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $25.61 | +173.33% | 1 | Apr 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $38.26 | -73.86% | 2 | Apr 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.49 | - | 2 | May 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $9.50 | +742.11% | 1 | Apr 19, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.00 | - | 2 | Nov 16, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $4.48 | +7,042.86% | 1 | Nov 8, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $4.83 | +16,670.19% | 1 | Feb 24, 2021 |
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $3.12
Upside: +573.08%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $22.00
Upside: +81.82%
Enliven Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $22.75
Upside: +18.68%
Acrivon Therapeutics
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.35
Upside: -
Oncolytics Biotech
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.12
Upside: -
Mural Oncology
Mar 25, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.48
Upside: -
CervoMed
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $7.21
Upside: +108.04%
Nuvation Bio
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $2.31
Upside: +332.90%
Beam Therapeutics
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $22.03
Upside: +54.34%
IN8bio
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $2.29
Upside: +1,472.05%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $2.55
Upside: +1,154.90%
Nov 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.73
Upside: -
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $8.37
Upside: +7.59%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $11.45
Upside: +48.47%
Sep 17, 2024
Initiates: Buy
Price Target: $13
Current: $3.06
Upside: +324.84%
Sep 11, 2024
Maintains: Buy
Price Target: $6 → $4
Current: $0.74
Upside: +440.69%
Jul 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.16
Upside: -
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $6.31
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $7.84
Upside: +231.84%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $25.61
Upside: +173.33%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $38.26
Upside: -73.86%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $3.49
Upside: -
Apr 19, 2023
Initiates: Buy
Price Target: $80
Current: $9.50
Upside: +742.11%
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.00
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $4.48
Upside: +7,042.86%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $4.83
Upside: +16,670.19%